Osteopontin, CD55:prognosticheskie faktory riskapri rake molochnoy zhelezy
Main Authors: | Zh M Guzieva, I V Poddubnaya, Ya V Vishnevskaya, N P Makarenko, K V Sytenkova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IP Habib O.N.
2011-09-01
|
Series: | Современная онкология |
Online Access: | https://modernonco.orscience.ru/1815-1434/article/view/29443 |
Similar Items
-
Faktory prognoza pri rake molochnoy zhelezy
by: A A Bozhok, et al.
Published: (2005-03-01) -
Bevatsizumab pri metastaticheskomi retsidiviruyushchem rake molochnoy zhelezy:metaanaliz randomizirovannykh issledovaniy
by: I V Kolyadina, et al.
Published: (2010-03-01) -
Allel'nye varianty v genakh BRCA1,BRCA2, TP53, assotsiirovannyes razvitiem raka molochnoy zhelezy
by: K V Sytenkova, et al.
Published: (2011-09-01) -
Novye vozmozhnosti endokrinnoy terapii raka molochnoy zhelezy
by: N P Makarenko, et al.
Published: (2001-09-01) -
Bevatsizumab v kombinatsii s khimioterapiey pri rake molochnoy zhelezy
by: Lyudmila Valentinovna Manzyuk, et al.
Published: (2013-09-01)